FDA’s One-Day Inspectional Assessments Pilot: A Risk-Based Shift in Oversight — What Regulated Entities Need to Know and How to Comply
Introduction
On May 6, 2026, the U.S. Food & Drug Administration (FDA) announced the launch of a pilot program for one-day inspectional assessments — a new, streamlined screening tool designed to make the agency’s inspectional resources more targeted and efficient. Then former FDA Commissioner Marty Makary, M.D., M.P.H., described the initiative as a way to “strengthen our inspectional approach by focusing our time and resources where they are most needed,” while minimizing operational disruption for lower-risk establishments. There is no indication from FDA that this initiative will change after Commissioner Makary’s recent resignation.
The pilot, which quietly began in April 2026, has already completed approximately 46 assessments across multiple FDA centers. Most have resulted in “No Action Indicated” (NAI) classifications, with inspectors retaining full authority to extend assessments if issues arise. This development arrives amid broader agency efforts to leverage data, artificial intelligence (AI), and risk-based prioritization — trends that will likely influence enforcement strategy for years to come.
What the Announcement Actually Says (and What It Doesn’t)
The official press release provides the primary public details. Key elements include:
- Purpose and Scope: Shorter, focused “screening assessments” that complement, rather than replace, traditional multi-day inspections. The pilot covers facilities involved in human and animal foods, biologics, medical products, and clinical research programs.
- Selection Criteria: Facilities are chosen using risk-based factors such as product type, prior inspection history, and operational characteristics. FDA noted that AI tools help identify low-risk sites.
- Flexibility Built In: Investigators may extend an assessment beyond one day (or convert it to a full inspection) if significant observations emerge. The program explicitly does not apply to higher-risk or complex facilities, as determined by FDA.
- Data Collection Goal: Findings will feed into improved risk models, helping FDA identify recurring compliance themes, generate facility-specific risk scores, and detect discrepancies between registered and actual operations.
- Timeline: The pilot runs through fiscal year 2026. FDA is developing evaluation metrics, including inspection duration, escalation rates, and utility of findings, before considering any broader rollout.
Important caveat: As of mid-May 2026, no detailed guidance document, Standard Operating Procedure (SOP), Federal Register notice, or inspection protocol has been released. The press release and Former Commissioner Makary’s remarks at the Food and Drug Law Institute (FDLI) Annual Conference represent the public record to date.
Legal and Regulatory Context
FDA’s inspection authority stems primarily from Section 704 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and related provisions of the Public Health Service Act. The agency has long employed risk-based inspection models, including under the Food Safety Modernization Act and various drug and biologics programs. The one-day pilot fits squarely within this framework: it does not alter underlying statutory obligations or enforcement policies. Instead, it adds a new, lighter-touch tool to FDA’s existing inspection toolkit.
Importantly:
- No change in enforcement posture — A one-day assessment can still result in Form FDA 483 observations, Warning Letters, or other enforcement actions if violations are identified.
- AI and data-driven selection raise transparency questions — FDA’s use of AI and data analytics to identify lower-risk facilities may raise questions regarding transparency and due process, although the pilot’s limited scope and voluntary nature (from the industry’s perspective) keep those issues largely theoretical for now.
- International implications — The pilot expressly includes foreign facilities, which could affect global supply chains and mutual recognition agreements.
Practical Implications for Industry:
Compliance and legal teams should view this pilot as an early signal of FDA’s evolving inspection philosophy: more frequent but more focused oversight, with an increased emphasis on demonstrable, real-time compliance controls.
Key takeaways:
- Perpetual readiness over “inspection readiness” — With shorter inspection windows, facilities cannot rely on last-minute document assembly. Robust quality systems, audit-ready records, and personnel who can clearly articulate processes under time pressure will become critical.
- Pre-inspection remote assessments may expand — The model appears to rely more heavily on documentation and data review before. or instead of during, the onsite assessment. Electronic systems, data integrity, and rapid export capabilities may therefore become even more important. Institutions and facilities should ensure that documentation is up-to-date and available upon immediate request.
- Low-risk status as a strategic asset — Companies that consistently demonstrate strong compliance histories and mature pharmaceutical quality systems may be more likely to qualify for these streamlined assessments, potentially reducing operational disruption and costs. Conversely, any history of inspection findings or recurring compliance concerns may keep a facility in the traditional, “full inspection” category. Institutions and facilities should continue strengthening FDA and research compliance programs, specifically around documentation retention and completeness, and compliance with policies and procedures.
- Clinical research and medical products sites should prepare — Sponsors, Clinical Research Organizations, device, drug and biologics manufacturers should consider incorporating one-day assessment scenarios into mock inspections and internal audit exercises.
- Documentation and response strategy — While the 15-day statutory windows for responding to a Form FDA 483 remains unchanged, facilities should prepare for heightened operational pressure. The current regulatory environment demands earlier identification of risks and a more robust audit-ready response strategy.
Looking Ahead
The FDA has indicated it will analyze pilot data before deciding on wider implementation. Regulated entities should monitor for:
- Future guidance documents or a draft inspection manual addendum.
- Public metrics regarding escalation rates and inspection outcomes.
- Potential expansion into additional program areas, such as compounding or combination products).
In the meantime, the announcement itself serves as a useful prompt for internal gap assessments, particularly around data integrity, rapid record retrieval, and management oversight.
Why This Matters
This pilot may signal a meaningful evolution in how FDA allocates inspectional resources and evaluates compliance risk. Although the initiative is framed as a streamlined assessment model for lower-risk facilities, it also reflects FDA’s broader movement toward AI-assisted oversight, data-driven enforcement, and more dynamic inspection strategies. For regulated entities, the practical implication is clear: facilities may be expected to demonstrate real-time operational compliance with far less advance preparation time and fewer opportunities to address deficiencies during a prolonged inspection. Organizations that maintain strong quality systems, accessible documentation, and a culture of continuous compliance will likely be best positioned as FDA continues modernizing its inspection framework.
Bottom line: This is not a relaxation of standards. It is a modernization of how FDA applies those standards, using improved risk signals and technology to inspect more facilities more efficiently. Companies that treat every day as though a one-day assessment could occur tomorrow will be best positioned — both for the pilot and for whatever comes next.
Foley is here to help you address the short- and long-term impacts in the wake of regulatory changes. We have the resources to help you navigate these and other important legal considerations related to business operations and industry-specific issues. Please reach out to the authors, your Foley relationship partner, our Health Care & Life Sciences Sector, or to our Health Care Practice Group with any questions.
